After reading this article years ago, I always wondered about my situation. My gleason is/way 4+3 (95% - 4) so basically gleason 8. My psa started to elevate in 2015 a a faster rate, when my PSA was at 10, I had IMRT and high dose brachytherapy. Two months later my PSA was down to 5, then I felt really sick for about three days, then went back to feeling normal but after that my PSA tests started showing increasing numbers. A doubling time of 3 weeks. I spew a lot of PSA in relation to the amount of cancer. At a PSA level of 38 in 2016, the CT scan showed no cancer (although the PSMA PET did show 3 hot spots).
My question is: Do you think this rapid psa increase would have occurred like this if I had done the prostatectomy or was this rapid increase caused by the radiation - maybe the cancer is radiation resistant or maybe the radiation escaped into my body (outside the prostate capsule) from the brachytherapy and caused me to feel that very unusual sick feeling in December, that coincided with when the PSA started to rise again?
The doctors don't have a clue. I suppose they don't think about this level of detail/cause. My concern is that it might be radiation resistant cancer, which the NIH doctor said, does happen to some, If it is radiation resistant then I might cause it to spread or mutate faster if I do spot radiation now. I suppose there is no way to know. I just wanted to see if any of you have any knowledge on this niche topic? It's just odd that I got really sick from either the cancer attaching to lymph nodes or it was from escaping radiation, and I wonder how that informs what kind of treatments to use going forward. So far, the Lupron only treatment has been effective and part of me wants to be aggressive and do radiation and add a 2nd line treatment and the other part of me says, maybe you should not mess with the success you've had so far.
This is an excerpt from the "prostate cancer lives as it was born" article:
health.harvard.edu/blog/pro...
"Over the study period, fewer and fewer men were diagnosed with advanced, late-stage prostate cancers that had spread beyond the prostate gland. This reflected the growing use of prostate-specific antigen (PSA) testing to diagnose prostate cancers earlier and earlier. In contrast, the proportion of high-grade cancers, as measured by the Gleason score, remained relatively stable rather than gradually becoming more aggressive. Previous studies have seen a similar pattern.
“It’s a very interesting study that confirms what previous studies have found,” says Dr. Marc B. Garnick, a prostate cancer specialist at Harvard-affiliated Beth Israel Deaconess Medical Center who was not involved in the study. “There may be rare exceptions, but in the vast majority the cancer is born with a particular Gleason score.”"
George